Email Updates

Search form

You are here


Oral tenofovir-based PrEP works. Faster, smarter rollout must be a top priority.

Recent clinical trials have shown clearly that daily, oral pre-exposure prophylaxis (PrEP) using the antiretroviral drugs tenofovir and emtricitabine dramatically reduces the risk of HIV infection for men and women who take it as directed. While PrEP won’t be right for every individual at risk for HIV, untold numbers of men and women will benefit—if they can access this potentially life-saving option.

So far, PrEP’s implementation has been piecemeal and incomplete. TDF/FTC is approved for use as oral PrEP in a handful of countries but, for maximum impact, PrEP rollout needs a coherent, global strategy involving many real-world demonstration projects, other research and guidance from global health agencies. At the same time, research into new PrEP formulations—such as intermittent use of pills or quarterly injections—could help improve adherence and achieve PrEP’s full potential.

What We're Reading

In a piece for, journalist and activist Jennifer Johnson Avril writes about community involvement (or lack thereof) in recent PrEP trials as well as the opportunities afforded by (and at times, limitations) of the Good Participatory Practice (GPP) Guidelines for stakeholder engagement in research.

August 7, 2017

POZ has this detailed look at the history of PrEP since it became available in the US in 2012.

July 13, 2017
Subscribe to RSS - PrEP